and that's just mismanagement. >> equally bad. >> which is why american express will get you done on your sell off. >> i'm melissa lee. thanks for watching. see you tomorrow at 5:00 my mission is simple. to make you money. i'm here to level the plaining feel for all investors. there's also a bull market somewhere, and i promise to help you find it. "mad money" starts now. hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends. my job is to make you money. my job is to enlighten and teach. call me or tweet me @jimcramer. it's rizic lus that the action in any one stock, any single stock could mean so much to the gigantic human stock market but
believe me when i say because of a huge corner of netflix, this could stay on a decline and move up nicely. dow climbing. s&p climbing and nasdaq climbing 72%. i know there are some people who will try to ascribe any strength to the market that the central bank will announce an initiative. buy a lot of assets. get europe going. these tend to be the same folks who think every move up or down are the same. we're all a bunch of puppets here right? if europe matters, it can only matter negatively. i won't mean a ching without the german nation saying they want to help out their neighbors. remember, their probalance budget, that's something that angela merkel aka in a pant suit prides herself on it. other people say that because interest rates could be going a
little higher stocks might break out of their funk because that would be a sign that the world is not coming to an end. sorry. the world not coming to an end is, again, not a reason to buy stocks. finally, you know what i heard what the president had to say about soaking the rich last night, and i know it ain't going to happen, so i'm not going to worry about it. again, that's a quaint thought. did anybody believe the president was going to pass this even though the house and senate are against him? no, whatever strength we had today was at least triggered, started by was the proximate cause of netflix. and the possibility that everything goes right with the stock that you own, you can still make a fortune in a day. oh netflix is an odd bird one of those stocks that people want to own because they love netflix, the service. now, there's nothing the matter with that. i kind of like that as a start to investing. i just kind of find it hard to value the stock which is i why
i call it cold stock. it trades on new releases like "house of cards," orange is the new black," and even marco polo." marco. >> polo. >> it turns out to be a bomb at the netflix office. it's both confidence-inspiring to all who own it and fear-inducing to so many of the pros who have been shorting it because the company disappointed the last couple of times, and they thought it would do it again. now, you know i play. today is no different. i know you could say netflix is part of the entertainment network. as the ceo and president and majordomo of netflix says there's plenty for both. the massive rally in netflix
today emboldens a ton of people to take action in lots of other speculative names, which is exactly what i would say was going to happen on friday's game plan. i said it would ignite a whole cohort. take, for example, tesla. here's one. chief sponsor morgan stanley cut its price target due to china's -- well debacle. they're not selling a lot of teslas there. again, tesla is a short stock. it's heavily valued and difficult to value. it's all about how cool the car is. i drove one. i wanted to say, wow i i'd like a piece of tesla because that's how it worked. if you called me i would object. they're too much alike. they really do trade together. witness the trade today despite, despite that cut by morgan stanley. how about amazon? i thought netflix took great pains last night to explain that they're not amazon that they're looking for material
profitability by 2017. do you think you would ever get a declaration like that from amazon? no way. that's what amazon lives for. no matter. amazon was off to the races. up $7.81 because amazon is again, a heavily shorted growth cold stock with substantial user/shareholder base. same issue with priceline. here's a stock that traded solely with the big speculative names, almost one for one. gets a lot of negative travel. all is frirch on day when netflix closed the doors off the earnings so it pole vaults more than 20 bucks. finally there's gopro. that's the quintessential, i like it so much i bought shares in the company equity. this stock has been a total bow wow. not today. boom. 3-buck rally. now, because netflix has a real tech component, you can buy it.
they feel like they're part of netflix. so google and apple get a boost. if they do, corvos and even sand disk which wasannounced the buyback. netflix cures all. well almost all. ibm reported last night and it was truly depressing -- depressing because the company cut numbers. ibm turning off a bunch of colossal seller. they told you it was going to have a down year at the beginning of january as anyone who has been fleeing the oils of late can tell you. like to analogize it to sports. you know what the difference is here between, say, the ibm and
nfl? ibm is going to lose right? and bad. at the bottom of the division. but they don't get a high draft choice because they failed to do well. there are no draft choices in this game and there's no medals for stocks down $4.80 in a single session. of course there was another positive. the key hmo you nighted health that was especially meaningful because last week they were downgraded. now, if you're a voracious short seller like a lot of the bozo hedge funds, this likes like a situation. we've also got two good bank quarters, this time from u.s. bane bank corp. they show you once again that the real problems are with the big and hard to understand and unwined banks. notice wells was almost back to when there was so much hammering
about that quarter, that it was a bad one. it was a good one, people. and we had oil stabilized that matters too. it's not the direction but the velocity. oil has now stabltized in the mid-40s which allows oil companies to catch their breath. that's how chev ron neighbors in weatherford can go up and down. here's the bottom line. this was indeed, a netflix day. people binged on speculative stocks. it's a day they finally had fear put into their thinking. do you know until today it was different? if a bad quarter got predicted it was eviscerated. netflix inspired trepidation among many key-eyed pes mist ss. that's exactly how a rally is born. why don't we start the question with ryan in california. ryan. >> caller: hi, jim.
thanks for taking the time. >> of course. >> caller: the company is lear core ticker lea. i'm concerned about a cyclicality. i've seen global auto growth projections anywhere from 1% to 5% in the next two years but with tesla, ford google and others adding components i feel there's plenty of room to run in the stock even if china or europe takes a header. what say you? >> this is exactly what we think for owners. we talk about this all the time. you want to be in the parts makers. you may not want to be in ford but you want to be in the carmakers. they continue to grow and grow. why don't we go to john in pennsylvania. john. >> caller: hey cramer. hay, i haven't owned any gold stocks for four years, and what i'm look at now being that it's around $1,300 it looks like it wants to kick through, i wanted
to look at gold stocks. gold corpse and anglo fields. is there any gold stocks you're interesting? >> the only mano we like is humano. we like rangel. riis toe dr. bristol. call in tomorrow -- maybe not tomorrow. call in friday. you are good. let's go to ted in arizona. >> caller: hey, jim. teddy in scottsdale, arizona. i'm 80 years old and depend on the dividends but the stock has gone down 20% in the past 90 days. i wonder what your feelings are of the future it's an oil stock, of course. >> i think it's fine. there was an upgrade today.
energy partners lp -- they abandoned that stock too soon. that is doing well. that is 6% yield. i think i prefer that. you know what we're going to do? we're going to go to sue in virginia. >> caller: hi, jim. thanks for taking my call. >> you're quite welcome. >> caller: here it is, phillip morris in 2008. >> i'm worried that this is the pmi guys not the m.o. i'm not as enamored of the stock as i once was. i'm not a fan favorite of p.l. phillip morris. okay. the equation's now changed after today. today's rally was triggered by netflix. isn't it great to know that if everything goes right with the stock you like you can still make a fortune in one day? on "mad money" tonight, a father and a u.s. navy reserviced who
became a biotech entrepreneur to save his children from a rare disease. it inspired a major movie featuring harrison ford. you don't want to miss that exclusive. then the netflix story is far from over. don't miss my take on a spot that -- stock that's about to shoot the lights out. i've got another player that could quadruple. could it do it again? i'll reveal. stick with cramer. >> don't miss a second of "mad money." follow @jimcramer on twitter. have a question? tweet cramer #madtweets. send jim an e-mail at madmoney @cnbc.com. or head to firstname.lastname@example.org.
>> yeah. >> this is john crowley. all the research is safe. >> i'm not on the verge of anything. >> how much would it take to prove your theory. >> i promised i would raise 500. >> is that ow? >>,000. >> is it 500 or a thousand? >> $500,000. the man i'm about to introduce you to is not your average businessman. john crowley is a father and u.s. sefsman who raised money to become a biotech entrepreneur to save his own kids from a rare disease. today his company f.o.l.d. is one of the hottest biotechs out there. it's speculative. it's a small company. it managed to rally 254% in 2014. that is some incredible performance. and i think there could be more upside if you're willing to take a risk in owning a piece of a
company that's inherently small. it treats small orphan diseases for people who desperately sma need treatments. they're working on treatments for a group of genetic conditions. for example, the company's lead drug candidate is mcgal staft for fabra disease which causes pain kidney failure and increased heart disease. basically giving the patients the enzymes they need but don't have. this drug is different. it stabilizes its own mutant enzymes. meanwhile the company's also working on a treatment for pompeii disease which is a progressively severe neuromuscular disease that can ultimately prove fatal even with existing therapies. right now they're using their plat fom to develop a next generation drug here and is currently facing two tries.
let's take a closer look with john crowley who's not just in this one for the money. he's a man on a mission to save his two children with pompeii disease including his daughter who happens to be here today. mr. crowley, welcome to "mad money." >> jim, it's a pleasure. >> have a seat. >> thank you very much. thank you. >> i went a little long on the intro dawes i want people to hear your story. usually i don't do this but i'm going to give you the floor. tell us what you're doing. >> thanks, jim. we got involved in biotechnology in the late '90s that two of our children got diagnosed with a rare disease, as you mentioned in the beginning, pompeii disease. at the time there was nothing. so we really focused as parents initially that what could we do to help drive science toward a cure. that was the initial effort and that led to the development of genzyme to a first gen racing treatment that our kids have now been on for more than a decade and it saved their lives and pa
rt of what we're trying to do at amicus therapeutics is what is the nextgen generation for pompeii. that's what brings us here today. a company that has an exciting platform and series of platform technologies and making medicines to fundamentally change people's living and do so with extraordinary science and that's kind of our story and where we are today. >> your family is here and we welcome megan to the show. >> absolutely. hello, megan. she's our sweetheart. she's 18 years old. >> we saw a clip of the movie. farley honest depiction. they take license. >> they do but i think they did a terrific job. it premiered five years ago today. it chronicled our journey over a five-year period to develop that first gen racing medicine. captured the family dynamic, the science, the challenges of drug
development. >> that's not the only medication. fa bray, that's something you're coming along with. what is that? >> people die of kidney failure, heart disease, involves oftentimes strokes with these patients. a devastating disorder. what we sought to do there is something fundamentally different. we wanted to develop a medicine that would be a pill and that's what ma gal stad is. so rather than an enzyme infusion where a patient would would take a drug through an i.v. bag hooked up to their arm every week for a therapy, what we've developed is a pill. that person living with fab ray will take it every other day and that's why we had such a transformative year in 2014. we had two late-state clinical studies with positive results, so it's a very exciting program for us. >> once again these are drugs
that it's met that need. it's a smaller number but without your drugs, the companies that typically pay for health care would have to spend far more taking care of these people than if they had that pill for instance. >> right. so we at amicus therapeutics work in the field of rare diseases and with that we're always working in devastating disorders where there are tremendous burdens on people living with the disease, their family members, people who care for them. and what we want to do again, is develop these life-saving therapies've when therapies exist, we want to try to do better. >> let's talk about this. what i find without slamming the big pharmaceutical companies but they temd to be a little slower than what you're talking about and not as focused on these populations. >> what we can do at amicus is we can focus like a laser beam
with an entrepreneur's patient and we can bring a very sharp patient focus. that's something very unique. you know i have our personal perspective in pompe disease and that's helped with the influence of the culture of the keep.company. and we have advocates. i ask them to think about it. if you were living with this disease, if you were a parent, is this something you would be excited about going into the clinic. that's kind of the fundamental basis. >> you're great. i'm not kidding. >> i've had so much help jim. >> no. a lot of people have sat there and said until you meet a parent who has this, you wouldn't understand the passion or, you know what people have this and it's $400,000 and united health would spend $600,000. you're living it and your family is living it and i'm sure everyone who's suffering from these horrible diseases appreciate it.
i know you're on a higher mission. i'm a stock guy. that's why i'm talk about about it. there are not that many people that have come with that much passion and involvement. i wish you the best of luck. >> thank you. >> i want to thank you. that's john crowley and his family. chairman and ceo of amicus therapeutics. stay with cramer. >> coming up netflix lifted the curtain reporting a monster quarter. tonight, the signs behind it that were hidden in plain sight but the plot thickens. could the earnings spot the next big mover.
could you see the netflix. could those upsides have been yours? so many times we've been blind sided by the good or bad on how they could be so wrong. how did they miss the sandisk disaster? how could they not have realized oil was coming down hard and fast? what didn't they see about how rue lieu was churning or how cvs was doing better than expected? but netflix? no. not only was this one available, but not one, two analysts nailed it and they nailed it perfectly.
upgrading the stock and urging you to buy, buy, buy ahead of the quarter. the work done by jock black ledge and others was exemplary and worked praising to the skies because you had plenty of opportunities to act to the upgrades. they gave you a lot of time both of which were rolled out when the stock was trading at 323. look at this thing. 323 and it's right now trading at 409. one week. what did they see? they did a survey of 1,000. largely because of original content and therefore a willingness to pay for netflix that. i have to. the pricing powers continue to increase over time because of the greater awareness including the critically panned marco polo. in fact the survey shows more netflix watchers watch "marco
polo" than "house of cards." this would continue to drive new subscribers, plus the desire of more binge watching shows that price increases won't be a problem and that could mean a dramatic increase in profitability down the road. although this didn't nail it in international sur scribers which took netflix to $67 million. it certainly made you want to buy the stock. while the potential price hike didn't figure in with analysts, the strength of the original programming did propel subscriber growth. this was a smart survey. it was brilliant work. i say well done.
he made a judgment that a huge increase in original programming would drive subscriptions aggressively and it would be a very inexpensive way to add subscribers because it happens to cost so much less. he even put out a number that sound ridiculous at the time. at least last week it could be 100 million subscribers by 2018. netflix is projecting so many by the end of the year. the good news is ceo reed hastings said because of the low cost of original programming and the ability of people to sign up at reasonable prices which i think means higher prices than now, the company will show material profitability in 2017. they plan on generating earnings out the wazzu. frankly the bottom line is i don't care how cowen or stevele got to you and told you and made you buy netflix. i don't care.
the truth is that either report offered enough compelling evidence to you to make you want to pull the trigger and the forecasts were just right enough to do that. so here's what i say. i say congratulations are in order all around from netflix's shrewd management to these two very smart analysts who are worth listening to who would have made you a ton of money had you acted on their recommendations. austin in california. austin. >> caller: hey, jim. how are you? >> i'm real good austin. how are you? >> caller: i'm grade. i have a question for you. i have some money invested in time warner cable. i wonder what you felt like in terms of what direction the company is heading in and if it stinks should i hold onto it. >> i like time warner twx, the entertainment company. i think that's what you want to be in. the cable company is involved in the merger. i like twx t one run by jeff bu cass, who, by the way, may i add
is great american. how about jude in new jersey. hi, jude. >> caller: hi jude. >> how are you? >> caller: good. thank you for all the money you made me. sorry about your dad's death. >> thank you. it's tough, but thank you for mentioning it. >> caller: i have a simple question for you. in the ebay environment, is it a good split up? >> i've got to study the conference call. i do like the fact that they're announcing a kind of rationalization. i know some people feel that guidance wasn't that good, but, remember, they're splitting and that's what matters. okay. sometimes analysts get it wrong but there were two who nailed it when it came to netflix. i'll give you a terrific opportunity to ride this higher and higher. there's much more ahead including my exclusive that soared over 300% last year.
medicine initiative to that bring us closer to curing diseases like cancer and debuy tees and give people the information they need to keep our families and ourselves healthier. we can do this. >> looks like the white house must have been watching our series, "biotech: the next generation." tonight i want to check in with one of the top five best performing biotechs from 2014, a stock that quad ruped last year but has pulled back over the last couple of weeks. that's tetx. specifically tg therapeutics is working on two drugs working on various blood cancers. both drugs are basically better versions. that's the emphasis. they can be taken in combination for even more powerful results. first there's tg 1101 a monaco antibody for nonhodgkins
lymphoma and chronic lymphocytic, ccl. plus tg 1101 can also treat some autoimmune diseases like rheumatoid arthritis. and then there's tg 1201, another drug designed to combat various drug cancers. this hits the same efficacy targets. it's a drug from gill yet but without the nasty side effects. even better tg therapeutics combine these two formulations and they're expected to run a phase 3 trial. now, after soaring last year the stock has pulled back more than four bucks since earlier this month. i've got to wonder if this is a buying opportunity. let's check in with michael weiss, executive chairman. mr. weiss, welcome to "mad money." have a seat. thank you so much.
>> thank you. >> it's very clear that what you're doing is taking a drug that a lot of people think is pretty good but has side effects and you're making it better. could you give us an example of what that's like? >> yeah. so basically we have two drugs and we're trying to make each one in their class better than it was before. so tg 1101 is our mon cal antibody. you know jim it's a $7 billion drug. >> huge. >> we've actually engineered that drug to have more activity. so we're looking at either reducing toxicity or adding activity or doing both. so in that particular case we're really focused on adding activity and we can actually see 50 to 100 times more potency than we see with writ toxin alone. on the other side tgr 1202, you noted that that's where we're having a living sparing effect. that drug was specifically designed to do that. we knew that the liver toxin was
going to be. it was engineered to specifically try to avoid that. we haven't seen any liver toxins. we think we're there. we're still doing some work. >> i went on that website. now they call id zt zydellic. that's one of the things. it pops up immediately as a warning and that's something you're addressing. >> right. we've seen a more mild effect. diarrhea and then the correlated diarrhea as it gets worse and worse turns into colitis and as you said they've had about 14% life-threatening severe colitis. we haven't seen it yet. we haven't seen the liver tox. we're off a different backbone. so when you think of what we're doing versus what they're doing, we've showed people the chemical structures ours is a different chemical backbone. it's more well tolerated. perhaps -- we haven't
definitively proven on the gi side effects. >> are you getting -- i was talking with my trainer whose mother unfortunately is doing some chemotherapy. i lost my mother to chemotherapy. how -- it's like prehistoric. every time my mom went in for chemotherapy, she was so much more sick. she got weak. are we aiming to try to stop that at last? >> yeah. 100%. from the moment we started this company, our goal was to remove chemotherapy from treatment regimens, and i think we as a group, us included in a group of companies is getting much closer. the key is to put the combinations together. >> right. >> nothing works on its own. i mean some things do work quite well, but to get to a cure, we need mum. drugs. we've seen it with hiv. >> the cocktails. >> the cocktails. we said we need cocktails of cognitive nature one that goes after killing the cancer without
killing the patient at the same time. >> your background is also finance. you did run a fund right? are some of those funds fungible and good and you understand the way stocks work? >> i probably understand it maybe too well but i definitely have a good appreciate. in terms of communicating the story and making sure that we're doing things the way investors would like us to do i think we have a pretty good sense of that. i'm also the largest shareholder of the company. from every perspective, i think i've got a shareholder's hat on at all times. >> it sure does. i hope you succeed because those who have lost loved ones oh, boy. that's michael weiss. the executive chairman of tg therapeutics. do some homework. it does sound attractive. "mad money" is back after the break.
sheldon. >> caller: boo-yah, mr. cramer. thanks for everything you do for everybody. boo-yah, sheldon. >> caller: i've been holding on to it for a long time. i don't see any reason why it's down as much as it is. i have a lot of it. i'm thinking of getting out of it. >> it's one of the ones that has that very troublesome yield. 14%, 15% yield which means it's a red flag which means i can't recommend the stock. jason in ohio. jason. >> caller: yeah, jim booyah. >> yeah man. >> caller: i have verizon pharmaceutical hmnp. >> we like all the pain place. we think there's room. you have to understand there's situations. as long as people realize they have to play with their mad money, i'm okay with it. i have to go to robert in new
york. >> caller: boo-yah. my situation is sejur. that said there are a lot of people that know if it would drop back to 42 it would go to eight. you do not need to sell it yet. understand it may not be complete if it's down to 42. let's go to ed in arizona. hey, ed. >> caller: i hone the airlines. >> i think could it repeat? >> i don't know. it's a great stock, great airline. i listen to dell tachlt delta's good. southwest tomorrow. i like it. mike in pennsylvania. mike. >> caller: boo-yah, jim. we're calling about rice energy buy or sell. >> i've got enough oil companies with really good differ accidentvidenddividends. i don't need to be in rice. if i had one that fit rice i
would be in core reo'or maybe in cimarex. phyllis in arkansas. phyllis phyllis phyllis. >> caller: hi, jim. i'm a huge fan. >> thank you. >> caller: i'm calling about greenbriar. we have a great need for their services but it seems to volatile. >> it's too volatile for me. they just reported a fantastic quarter but i do think there will be fewer cars ordered. why? i think the railroad business the oil part is going to be slowed down. he's got best in show. i think you should scale out over time. neal in new hampshire. >> caller: hey, jim. boo-yah to you. >> what's up? >> caller: what about old dominion freight line. >> people feel trucking companies are not having a good quarter and they're not benefiting. diesel fuel, by the way, it has not fallen as much as regular gasoline. i think old dough min downis fine. let's go to gerrard in nevada.
gerard. >> caller: hey, jim. a great big boo-yah to you from 7,000 feet. >> what's going on there? >> caller: the weather's great. >> we had a guy who bought whole deckers. he drove it down and a series. my feeling deckers is you hold it long team because martinez is one of the smartest people in the footwear business. you want the long-term. what he's going to do with hoe ka yoga shoes, running shoes and ugg. giving up is the wrong thing to do. charles in arkansas. charles. it was a real jam-up and is disappointing. it was very expensive. if you want cost-efficient
benefits, it's not the exact same kind. let's go to mac in kentucky. please, mac. >> caller: cramer. >> yes. >> caller: big blue nation boo-yah to you. >> that was spirited. what's going on. >> caller: i want to know if we're out of the ash heap raise above the flames and get a move up on sprint. >> sprint. there's a lots of talk between sprint and google tie-up and a sprint and t-mobile tie-up with google. all this is tuck. all of it is rumor. hold onto sprint for the long term. it's too low to sell and they've got a big backer. i think they'll be okay. john from indiana. >> caller: boo-yah, jim. >> yes, what's happening ginnie mae integrated. >> i hear good things. i still like intel even after that quarter but cyprus to me represents good value and
you don't want to be caught up in that crossfire. so let's play. this is where you call me and tell me your top five holdings and i tell you if your partnership is diversified enough or needs to be mixed up a little little. speaking of cold stock let's start with a tweet. here we have a tweet from from @cramershirt. apple, jcp, time westerner, epd, and ua. #amdiversified. let's go to work. all right. underarmers clothing. time warner's entertainment. uh-oh. jcpenney, retail. these will trag today. i'm going to say ixnay on jcpenney and good-bye. cramer understands this and it surprises me. bristol-myers. okay. let's do the next one. we've got who is this drew in california. drew. >> caller: hey, jim.
how are you doing? >> i'm doing well. how about you? >> caller: good good. first-time caller long testify-time listener. >> skblejt. >> caller: keep in mind my stocks have increased in ten years. am i diversified. 3m johnson and johnson, kimberly-clark mcdonald's and proctor and gamble. >> these are concerns. i would lump kimberly-clark and p and g. they're both good stock. i'm not that happy with how much j & j has been working. same with mcdonald's. so we have one consumer package. we're getting rid of another. we've got 3m. diversified striflindustrial.
and you know what i want to add? let's do disney. disney would take the place and give us a disney play. let's go to mike in nebraska. mike mike mike. >> caller: hello, jim. >> mike. >> caller: my five stocks are union pacific union. >> let's see what we have here. we've got a rail and maybe the best rail. altria tobacco company. airlines, southwest, apple technology. don't trade it. just own it. and alibaba group. i'm putting that as a speculative. that's a speck, okay? that trades with netflix.
speculative, rail tobacco, tech, airline. i like it! ken in georgia. ken. >> caller: boo-yah, mr. cramer. >> boo-yah, ken. >> caller: first-time caller. i would like to commend you and your staff on such an educational program. >> thank you, man. that's what we're trying to do. we're trying to illuminate. let's go. >> caller: good. my five stocks are an geous, eggn blackstone group, bx jack henry & associates incorporated jkhy dominion resources incorporated d, 3m mmm. >> all right. let's go to work. okay. blackstone group private equity one i've been recommends. 3m 3m, diversified. dominion may be my favorite utility play. ee jen sus, we had them on.
they're coming. what do i do? you need to catch the 4:10 huh? the equipment tracking system will get you to the loading dock. ♪ there should be a truck leaving now. i got it. now jump off the bridge. what? in 3...2...1... are you kidding me? go. right on time. right now, over 20,000 trains are running reliably. we call that predictable. thrillingly predictable.
you know we've been all over it from pepsi to dow chemical of course to dupont. tomorrow we've got a beg one on cnbc. carl icahn will be going toe to toe with the-time traders and my good friend judge wapner. you know i'll be watching to hear what he has to say about ebay which reported okay, nothing great, and a whole lot more. i also want to hear how bad sandisk was and the credit card companies. looks like december was a tough month. i want to drill on those. don't forget to do your homework on any of the biotechs that i say are speculative. i always promise you there's a bull market somewhere. i try to find it for you on "mad money." i'm jim crime eric and i'll see you tomorrow.
>> right now on the "car chasers"... it's a feeding frenzy when meg and i hit one of the largest auto swap meets in the country. oh, look at that. it's a little cameo truck. >> this truck needs everything. >> if i buy the truck, i'm gonna nickname it... >> both: "everything." >> plus, i take a shot at the perfect period-correct wagon owned by my protégé, billy hayes. >> i love the car! >> oh, i don't love the car? >> not like i love this car. >> man. >> but with billy, it always gets personal. >> are you listening to what you're saying? >> i am! >> you're out of your mind! [ engine revving ] >> i'm jeff allen, and i buy fix, and flip cars. along with meg, my partner in crime, and eric, our mad scientist, we're flat 12 gallery. my main competition is still my dad, the toughest negotiator i know.